Strides Pharma Science Ltd · NSE:STAR
Strides Pharma Science — Shareholder Meeting (September 2022)
11 slides from Strides Pharma Science's shareholder meeting presentation, September 2022
Slide 1: Warm Welcome to Shareholders
Warm Welcome to Shareholders Strides Pharma Science Limited Annual General Meeting September 2022
Slide 2: Agenda
Agenda Strides at a Glance FY22 Performance FY23 Outlook & Stelis Updates AGM Agenda
Slide 3: Strides is a global generic formulations player across regulated and emerging markets
Strides is a global generic formulations Player with presence across key regulated and emerging markets Core Business Fundamentals Propelling Growth & Value Creation Diversified High End presence in Regulated Strong go to market capabilities in US, UK, Europe, Australia, South Africa Manufacturing a
Slide 4: FY22 has been a difficult year with lowest ever EBITDA performance
FY22 has been a difficult year with Strides reporting its lowest ever EBITDA performance Consolidated Performance (₹m) ◎ Fall in US revenues due to covid-related headwinds leading to drop in Particulars FY22 FY21 YoY volumes ◎ Significant margin compression due to the heightened competitive intensit
Slide 5: Strides guides for an encouraging FY23 with focus on growth, cashflows and debt reduction
Strides guides for an encouraging FY23 with focus on growth, higher cashflows & reduction in debt Growth Cost Improvement Plan (CIPs) Debt Reduction target of ~ ₹10bn in FY23 Bounce back in the US markets led by new product launches from A significant reduction in investments in R&D for the US, Targ
Slide 6: Strides reported improved performance in Q1'23
Strides reported improved performance in Q1’23 Q1FY23 Consolidated Performance (₹m) ▸ US revenues at ₹3,552m ($46m) for Q1FY23 versus ₹3,016m ($41m) in Q1FY22 up 18% YoY Particulars Q1 FY23 Q1 FY22 YoY US business continues ▸ Adjusted for customer transition spill for Chestnut ridge portfolio of $5m
Slide 7: Update on Stelis Biopharma
Update on Stelis Biopharma
Slide 8: Promising beginning for Stelis with USFDA and EUGMP certification
Promising beginning for Stelis as we received USFDA and EUGMP certification for our facilities A high capital long gestation investment now ready for significant growth and operational profitability • Stelis has emerged as a biopharmaceutical company with integrated capabilities in developing, scale
Slide 9: AGM Agenda
AGM Agenda
Slide 10: Agenda for AGM
Agenda for AGM Item 1: Adoption of Audited Financial Statements for the Financial Year ended March 31, 2022 ORDINARY Item 2: Re-appointment of Mr. Badree Komandur, retiring director, as an Executive Director BUSINESS Item 3: Re-appointment of M/s. B S R & Co. LLP as Statutory Auditors of the Company
Slide 11: Thank You
Thank You Strides Pharma Science Limited CIN: L24230MH1990PLC057062 REGISTERED OFFICE 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924/ 2789 3199 Fax: +91 22 2789 2942 Email: corpcomm@strides.com Website: www.strides.com CORPORATE OFFICE Strides House, Bilekahalli
Strides Pharma Science — Shareholder Meeting (September 2022) on 6ix